Advertisement

Topics

De Novo Pharmaceuticals Ltd Company Profile

22:39 EST 12th December 2018 | BioPortfolio

The volume of structural protein data that will emerge in the next few years will serve as a driver that transforms the pharmaceutical industry. Over the next decade it is predicted that the high-resolution 3-D structure of all proteins that precisely define the biological space of human, pathogenic organisms and plant proteomes will be available. As this flood of data on proteins becomes available, De Novo is centrally positioned to efficiently link biological space to chemical space.

Location

Compass HouseVision ParkHiston
Cambridge
Cambridgeshire
CB4 9ZR
United Kingdom

Contact

Phone: 44 (0)1223 238000
Email: info@denovopharma.com


News Articles [849 Associated News Articles listed on BioPortfolio]

Deals and M&As this week: Tolero Pharmaceuticals, BioNTech, Novo Nordisk

Tolero Pharmaceuticals has entered a clinical research collaboration with AbbVie for the development of a therapy for acute myeloid leukaemia...Read More... The post Deals and M&As this week: Tol...

Mirum Pharmaceuticals brings in $120mm through Series A round

Mirum Pharmaceuticals (developing treatments for pediatric cholestatic liver diseases) raised $120mm through its Series A round. New Enterprise Associates led and was joined by Deerfield Management, F...

BB-Biotech-Beteiligung Novo Nordisk setzt Konkurrenz unter Druck

Novo Nordisks Insulinpens werden smarter. Im heiß umkämpften Diabetesmarkt scheinen sich die Dänen erneut einen Vorteil gegenüber der Konkurrenz zu erkämpfen. Im kommenden Jahr will Novo seine er...

Novo Nordisk Cutting 250 More Jobs, This Time in U.S.

Novo Nordisk confirmed today it will eliminate 250 U.S. jobs in business functions—the company’s second set of workforce reductions worldwide in as many weeks. Of the planned job cuts, 100 are...

Novo Nordisk cuts 1300 jobs in the midst of Trump's pricing pressures and depreciation of US dollar

Danish multinational Novo Nordisk has said that they will have cut 1,300 employees by the end of 2018. The decision has come partly in response to the Trump administration’s efforts to reduce the pr...

Novo Nordisk-Aktie: Entscheidend ist die Nachrichtenlage

Kulmbach (www.aktiencheck.de) - Novo Nordisk-Aktienanalyse von "Der Aktionär": Marion Schlegel, Redakteurin beim Anlegermagazin "Der Aktionär", nimmt die Aktie von Novo Nordisk (ISIN: DK0060534915,....

Insulinhersteller Novo Nordisk kauft britisches Start-Up

Der dänische Insulinhersteller Novo Nordisk verstärkt sein Diabetes-Geschäft mit einem Zukauf. Wie Novo Nordisk am Freitag in Kopenhagen mitteilte, übernimmt der Konzern das britische Start-Up Ziy...

Novo begins R&D tie-up with AI biotech e-Therapeutics

Novo Nordisk has signed a deal with UK biotech e-Therapeutics to use its AI-based drug discovery technology to find new therapies for type 2 diabetes. e-Therapeutics will work with Novo for a year an...

Drugs and Medications [296 Associated Drugs and Medications listed on BioPortfolio]

Novolin [Novo Nordisk]

Novolin 70/30, 70% NPH, Human Insulin Isophane Suspension and 30% Regular, Human Insulin Injection (recombinant DNA origin)

Novolin [Novo Nordisk]

NOVOLIN N Human Insulin Isophane Suspension (recombinant DNA origin) 100 units/mL

Pur-wash [Niagara Pharmaceuticals Inc.]

Pur-Wash

Myfortic [Novartis Pharmaceuticals Corporation]

Myfortic (mycophenolic   acid*) delayed-release tablets *as mycophenolate   sodium Rx only Prescribing Information

Novolin [Novo Nordisk]

Novolin 70/30, 70% NPH, Human Insulin Isophane Suspension and 30% Regular, Human Insulin Injection (recombinant DNA origin)

PubMed Articles [407 Associated PubMed Articles listed on BioPortfolio]

Swimming activity in zebrafish larvae exposed to veterinary antiparasitic pharmaceuticals.

Veterinary antiparasitic pharmaceuticals have been detected in surface waters and several of these pharmaceuticals act on the nervous system on the target organisms implying that neurological effects ...

Chiral pharmaceuticals: Environment sources, potential human health impacts, remediation technologies and future perspective.

Chiral pharmaceuticals (CPs), including non-steroid anti-inflammatory drugs (NSAIDs), β-blockers and some herbicide and pesticides, are widely used in aquaculture, clinical treatment and many other f...

Assessment of 83 pharmaceuticals in WWTP influent and effluent samples by UHPLC-MS/MS: Hourly variation.

The removal efficiency of pharmaceuticals in wastewater treatment plants (WWTPs) is variable and some of these compounds pass these plants almost intact and others presenting a removal efficiency clos...

novoCaller: A Bayesian network approach for de novo variant calling from pedigree and population sequence data.

De novo mutations (i.e., newly occurring mutations) are a predominant cause of sporadic dominant monogenic diseases and play a significant role in the genetics of complex disorders. De novo mutation s...

Effects of pharmaceuticals on microbial communities and activity of soil enzymes in mesocosm-scale constructed wetlands.

Cyperus alternifolius based mesocosm-scale constructed wetland was employed to remove pharmaceuticals. We investigated the microbial community composition using phosphor lipid fatty acids (PFLAs) anal...

Clinical Trials [611 Associated Clinical Trials listed on BioPortfolio]

Evaluating Therapeutic Response to Novo-TTF

This study is to assess the utility of high resolution 3D echo planar magnetic resonance spectroscopy (3D EPSI) in monitoring Novo-TTF response in glioblastoma multiforme (GBM) patients.

Bioequivalence Study of Torrent Pharmaceuticals's Ltd's Nebivolol 20 mg Tablet

Subjects to compare the single dose bioavailability of Torrent's Nebivolol Tablets 20 mg and Bystolic 20 mg Tablets of Forest Pharmaceuticals Inc., USA. Dosing periods of studies were sepa...

Bioequivalence Study of Torrent Pharmaceuticals Ltd's Nebivolol 20 mg Tablet

Subjects to compare the single dose bioavailability of Torrent's Nebivolol Tablets 20 mg and Bystolic®20 mg Tablets of Forest Pharmaceuticals Inc., USA. Dosing periods of studies were sep...

De Novo Pilot Study, Lutonix Catheter in Conjunction With Bare Metal Stenting for Treatment of Coronary De Novo Lesions

The study will enroll patients with angiographically significant coronary de novo lesions. Subjects will be randomized 1:1 and treated with a Lutonix catheter either before or after bare-m...

Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects in Fed Condition

- Objective: - The objective of this study is to compare the rate and extent of absorption of the Test Product, Citalopram Hydrobromide 40 mg (Torrent Pharmaceutical Li...

Companies [1389 Associated Companies listed on BioPortfolio]

Novo A/S

Novo A/S is fully owned by the Novo Nordisk Foundation and is the holding company of the Novo Group. Novo A/S is a private limited liability company and the majority shareholder in the publicly listed...

Novo Nordisk A/S

Novo A/S, the holding company of the Novo Group, is fully owned by the Novo Nordisk Foundation and was established to manage the Foundation's funds and to invest actively in other companies. What make...

De Novo Pharmaceuticals

The commercial focus of De Novo is the exploitation of human genomics in drug discovery through in silico drug design. The company attracted £2 million financing in a first VC-backed investment roun...

Novo Nordisk, Inc.

Novo Nordisk is a global healthcare company with more than 87 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy...

De Novo Pharmaceuticals Ltd

The volume of structural protein data that will emerge in the next few years will serve as a driver that transforms the pharmaceutical industry. Over the next decade it is predicted that the high-reso...

More Information about "De Novo Pharmaceuticals Ltd" on BioPortfolio

We have published hundreds of De Novo Pharmaceuticals Ltd news stories on BioPortfolio along with dozens of De Novo Pharmaceuticals Ltd Clinical Trials and PubMed Articles about De Novo Pharmaceuticals Ltd for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of De Novo Pharmaceuticals Ltd Companies in our database. You can also find out about relevant De Novo Pharmaceuticals Ltd Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...


Corporate Database Quicklinks



Searches Linking to this Company Record